EGP-2, also known as Ep-CAM, is expressed at high levels on the surface of most carcinomas and is therefore considered an attractive target for anticancer strategies. To explore the mechanisms regulating the expression of EGP-2, sequences 3.4 kb upstream of the transcription start site were isolated and assayed for their ability to control the expression of the EGP-2 cDNA, the green fluorescent protein, the luciferase reporter gene and the thymidine kinase and cytosine deaminase suicide genes. Expression of these chimeric constructs as assessed in a range of different cell lines was restricted to cell lines expressing EGP-2. In addition, only cells expressing EGP-2 were sensitive for gancyclovir after being transiently transfected with EGP-2 promoter-driven thymidine kinase. Deletion analyses defined 687 bp upstream as the basic proximal promoter region, which could confer epithelial-specific expression to the GFP reporter gene in vitro. As these EGP-2 sequences can confer promoter activity to reporter and suicide genes in an EGP-2 restricted manner, they may be useful for gene therapy of EGP-2 expressing carcinomas.
D
espite numerous improvements in radiological, chemotherapeutical and surgical techniques, current treatments for metastatic malignant disease are often ineffective. Therefore, new treatment strategies, which can enhance the selectivity of systemic therapy so that tumor response is increased without toxicity to normal tissue, have gained interest. 1 In this respect, gene therapy provides an attractive option, in combination with promising suicide gene/prodrug systems as effector mechanism. 2 However, a major impediment to the development of gene therapy treatments is the lack of suitable expression cassettes for directing selective transgene expression. The epithelium specific but highly abundant expression of the human epithelial glycoprotein-2 (EGP-2) makes it a useful target for carcinoma directed treatment modalities, such as EGP-2-restricted gene therapy. The 38 kb EGP-2 protein, also referred to as Ep-CAM or 17-1A, is encoded by the GA733-2 gene. 3 Although it has been described as a homotypic adhesion molecule and as ligand of the leukocyte-associated immunoglobulin-like receptor (LAIR-1) the physiological function of EGP-2 is still unclear. [4] [5] [6] Since its discovery in 1979, numerous immunotherapeutical strategies using EGP-2 as a target have been developed and are at present used in clinical settings. 7, 8 Use of the EGP-2 protein's carcinoma specificity for the development of gene therapy strategies, however, has been held up by the fact that the regulatory sequences directing this specificity had not yet been characterized.
Here, we describe the isolation of the 5 0 sequences from the GA733-2 gene and the identification of cis-acting sequences needed for selective expression of heterologous genes in EGP-2-positive cells. By deletion analysis, the basic proximal promoter region capable of directing expression in an EGP-2-restricted manner was defined. Subsequently, the EGP-2 transcriptional regulatory sequences were successfully used to direct transient, carcinoma-specific expression of the cytosine deaminase (CD) and thymidine kinase (TK) suicide genes. The use of these constructs, especially in combination with an EGP-2-specific gene delivery system as has been developed recently, 9 should enhance the safety and efficacy of vector-based carcinoma-specific gene therapy approaches.
(FLF) were isolated in 1992 under informed consent and the human umbilical veins endothelial cells (HUVEC) are isolated on a weekly bases under informed consent. 11 The human colorectal adenocarcinoma cell line SW948 (CCL 237), ovarian carcinoma cell line SKOV 3 (HTB 77), glioblastoma cell line U373 MG (HTB-17), the mouse melanoma cell line B16-F10 (CRL 6475), and the SV40 transformed simian kidney cell line COS-7 (CRL 1651) were obtained from the American Type Culture Collection (Manassas, VA). All cell lines were cultured in the recommended growth medium and maintained in a 371C atmosphere containing 5% CO 2 .
Cell transfection
The cells were transfected using the cationic lipid transfection reagent Saint (Synvolux Inc., Groningen, The Netherlands) in a six-well plate with 0.5 mg DNA per well following the manufacturer's protocol. To correct for differences in transfection efficiency, transfection experiments were carried out in triplo and repeated at least 3 times with freshly isolated plasmid DNA. 12 
Isolation and cloning of the EGP-2 promoter region
For the isolation of the EGP-2 5 0 promoter region, a BAC genomic library was screened by GenomeSystem, Inc. (St Louis, MO) with a 400 bp [ 32 P] -genomic DNA fragment containing 200 bp of the 5 0 region of the EGP-2 gene in addition to a part of exon 1. The probe was derived by digestion with SalI/SacII of the GA21726-22RS vector, kindly provided by Dr Linnenbach (Wistar Institute, Philadelphia). DNA from a positive clone was purified according to standard methods for BAC DNA isolation and analyzed by restriction mapping and Southern blot analysis. A 4.2 kb spanning SacII/BglII genomic subfragment containing at least part of exon 1 and approximately 4 kb of upstream sequences was identified and isolated from the BAC vector and cloned into the SacII/BamHI sites of the pBluescript SK plasmid (Stratagene, Inc., San Diego, CA). This construct was then subjected to further restriction mapping and DNA sequence analysis using the thermo sequenase primer cycle sequencing kit (Amersham-Pharmacia, Biotech., Piscataway, NJ) with Cy5-labeled primers (Eurogentec, Seraing, Belgium) on the ALF-express sequencer (Amersham Pharmacia, Biotech.). DNA sequence data were managed and analyzed by the DNA Star computer program (DNA Star Inc., Madison, WI). Consensus sequences of transcription factor binding sites were identified using the TRANSFAC v3.2 database. 13 The 4.2 kb SacII/BglII sequence was submitted to the gene bank accesion no. AY148099.
With XmaIII 3.6 kb of EGP-2 promoter sequences without the ATG were seized out of the SacII/BglII promoter fragment and recloned into the NotI site of the pBluescript SK vector (Stratagene, Inc., San Diego, CA). Via subsequent digestion with XhoI/SacII 3.4 kb of the promoter sequence was cloned into the luciferase reporter pGL3-basic vector (Promega Inc., Madison, WI). Digestion of a pBluescript construct containing the promoter sequence in the reverse orientation with SacI/XhoI yielded a 3.4 kb promoter fragment that was cloned into the GFP reporter plasmid pEGFP-1 (Clonetech, Palo Alto, CA).
Deletion constructs of this 3.4 kb EGP-2 promoter region containing pEGFP-N1 vector further referred to as p39 E , were generated using a double-stranded Nested Deletion Kit (Amersham-Pharmacia, Biotech.). Following the manufacturer's protocol deletion constructs were generated using BglII to generate the recessed 3 0 -ends which were filled in with thionucleotides to make them nuclease resistant and SpeI to create a 5 0 -overhanging nuclease-sensitive end. The generated EGP-2 promoter constructs chosen to be used in transfection experiments were; p39 E (À3340/ þ 93); p39 E4-7 (À2705/ þ 93); p39
E12-3 (À57/ þ 93), and p39 E12-2 ( þ 9/ þ 93). The numbers between the brackets refer to number of basepairs relative to the putative transcription site (Fig 2) . Digestion of the p39 E vector with PstI and subsequent ligation resulted in p39
EPstI31 (À177/ þ 93) and p39
EPstI26
(À3340/À2803 and À177/ þ 93) deletion constructs. Upon digestion with XcaI and ScaI a 306 bp fragment covering a putative ESE-1 site was deleted from the p39 E vector resulting in p39 E-ESE1 (13340/À2407 and -2097/ þ 93). In addition, the CMV promoter was excised from the pcDNA3 vector (Invitrogen, Breda, The Netherlands) by BglII/HindIII digestion and cloned into the multiple cloning site of the pEGFP-1 plasmid as a positive control, yielding p39
CMV . The empty pEGFP-1 vector was used as negative control.
The EGP-2 promoter-EGP-2 cDNA construct was generated by exchanging the HindIII/XbaI luciferase gene of the pGL3-basic vector with the HindIII/XbaI EGP-2 cDNA fragment isolated from the CDM8 GA733-2 vector, kindly provided by Dr Linnenbach (Wistar Institute, Philadelphia). Subsequently, the À3967 to þ 74 EGP-2 promoter region was fused to the cDNA by ligation in the KpnI/StuI site. To clone the EGP-2 promoter upstream of the Cytosin Deaminase cDNA, the XbaI/SacI EGP-2 promoter fragment was subcloned into the pSL301 superlinker vector (Invitrogen) and cloned in the SpeI/NheI sites upstream of the CD gene situated in the NheI/PmeI sites of the pSecTag vector (Invitrogen). The EGP-2-promoter HSV-TK construct was generated by exchanging the BglII/BamHI CMV promoter fragment of the pcDNA3.1-TK construct with the BamHI EGP-2 promoter fragment isolated from the p39 E vector. Both the pSecTag-CD as well as the pcDNA3.1-TK plasmid were kindly provided by Dr H Haisma, RuG, Groningen, The Netherlands. An overview of the plasmid constructs generated is shown in Figure 1 .
Analysis of expression
GFP expression was studied by microscopic and flow cytometric analysis using the Leica Quantimed 600 (Leica, Rijswijk, The Netherlands) and the Coulter Elite Cytometer (Coulter Electronics, Hilaleah, FL) and immunohistochemically using the anti-GFP polyclonal antibody (Molecular Probes, Eugene, OR 
Â%gate ðR2Þp39
CMV ÞÂ100%
Luciferase activity was measured using the Promega luciferase assay system (Promega Inc., Madison, WI) and light output recorded by the Anthos, Lucy 1 luminometer (Anthos Labtec Instruments, Salzburg, Austria). The relative luciferase expression (luc. exp.) was determined using the promoterless pGL3 vector as background control and the CMV promoter-driven luciferase expression (pGL3 CMV ) was set at 100%. The relative expression level of the luciferase of the rest of the constructs was deducted using the following equation:
CMV luc: exp :ÞÂ100%
The EGP-2 expression was determined immunohistochemically using undiluted tissue-culture supernatant of the anti-EGP-2 hybridoma MOC31 (IgG1; IQ products, Groningen, The Netherlands). The antibacterial cytosine deaminase monoclonal antibody 16D8F2 kindly provided by Dr K Haack, (Chirurgische Universita¨tsklinik, Heidelberg, Germany), was used to identify CD-positive cells. The 9E10 c-myc peptide recognizing monoclonal antibody was used to identify TK expressing cells.
14 Horseradish-peroxidase-conjugated rabbit anti-mouse Ig and goat anti-rabbit Ig (Dakopatts, Glostrup, Denmark) were used as secondary antibodies.
EGP-2 PCR
The presence of the GA733-2 genomic sequences was determined by PCR of the last exon, exon 9 (sense strand 5 0 -TCAGATAAAGGAGATGGGTGAGA/antisense strand 5 0 -GGCAGCTTTCAATCACAAATCAG) and the promoter region from -1687 to -406 (sense strand 5 0 -CCGGCACTTCAACAGAATACAA/antisense strand 5 0 -GAACGTGGAGGCTAAAGGAAATAC). The presence of the GAPDH gene was used as control on the amount of genomic DNA (sense strand 5 0 -CCATCACTGCCACTCAGAAGACT/antisense strand 5 0 -TTACTCCTTGGAGGCCATGTAGG).
Measurement of sensitivity to gancyclovir (GCV)
SKOV-3 (EGP-2 positive), U373 MG (EGP-2 negative) and B16-F10 (EGP-2 negative) cells transiently transfected with CMV-TK, EGP-2-TK or CMV-GFP were plated 48 h after transfection in 96-wells plates at a density of 1 Â 10 4 cells/well in recommended media. All of the experiments were performed in triplicate and repeated at least three different times. The cells were treated with various concentrations of GCV (Sigma, Bornhem, Belgium) for 4 days starting 24 h after replating. Sensitivity to GCV was evaluated using the colorimetric MTT assay as described previously. 15 A multiwell scanner was used to measure the absorbance at 570-630 nm dual wavelengths. The nontransfected untreated controls were assigned a value of 100%.
Results
Screening of a BAC genomic library (Genomic Inc.) with a 5 0 GA733-2 probe yielded a positive clone, which was characterized by restriction enzyme mapping, PCRscreening, and nucleotide sequencing. To define the GA733-2 promoter region, restriction analysis with SacII and double digests with SacII and a number of other enzymes were carried out (Fig 1a) . Since a SacII site is positioned 40 bp downstream of the ATG it was shown by Southern blot hybridization with a SalI/SacII fragment of the 5 0 GA733-2 probe that the BAC clone contained at least 10 kb of GA733-2 upstream sequences (Fig 1a, lane  1) . Double digestions with SacII and BglII or EcoRV revealed bands containing part of exon 1 and approximately 4 or 5 kb of upstream sequences, respectively (Fig  1a, lanes 7 and 8) .
Sequencing of the cloned BglII/SacII 5 0 GA733-2 promoter region yielded 4.2 kb of sequence upstream of the longest reported 5 0 untranslated region of the EGP-2 cDNA (Fig 2) . 16 This upstream region lacked the canonical TATA and CAAT boxes commonly found within 100 bp upstream of the putative transcription site. However, regulatory elements competent to initiate transcription including the consensus initiator element (3), cells and the H2O control (4) using primers covering the last exon, number 9, the EGP-2 promoter region, or the GAPDH gene. The presence or absence of endogenously expressed EGP-2 and expression of GFP upon transfection of the p39E vector are indicated by either a plus ( þ ) or a minus (À) symbol.
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(YYANWYY) which position matches with the putative transcription initiation site and GC boxes were present. An E-box sequence is also present, however at position -1753. The NF-kB transcription-binding site involved in the downregulation of EGP-2 by TNFa in squamous cell carcinomas is located in proximity of both the Inr and the ATG. Screening of the proximal 5' flanking region for consensus recognition sequences of transcription factors that are known to be involved in epithelial-specific gene expression revealed putative cis-acting regulatory elements (Table 1) . Proximal to the transcription start Ets and Sp1 transcription factor binding sites were identified. Several epithelium-specific genes, such as transglutaminase-3 (TGM-3) and keratin 18 (K18), have been shown to depend on Ets factors for epithelial cell transcription. Ets members generally cooperate with other transcription factors and it has been demonstrated that epithelialspecific expression can be directed by cooperative interactions between Sp1 and Ets transcription factors. The EGP-2 promoter also contains a consensus binding site for the activator protein-1 (AP-1) and AP-2, which have been implicated in the epithelial specific expression of the K18 and a6 integrin genes, respectively. Of further interest is the presence of an ESE-1 (epithelial-specific ets-1) consensus binding site at -2167 at the (-) strand. No consensus sequences homologous to the E-pal sequence, which has been reported to direct the epithelial-specific transcription of the E-cadherin gene, could be detected following the consensus sequence (CANNTG) 2 . However, imperfect E-pal-like sequences harboring the CANNTG consensus binding site for the helix-loop-helix transcription factors at only one site could be found at positions -1062 and -181 of the EGP-2 promoter. No keratinocytespecific transcription factor Ker-1 binding site often present in the promoter region of the keratin genes was detected.
To verify that the proximal 5 0 flanking region contained a functional promoter capable of directing cell-specific heterologous gene expression, the reporter genes luciferase and GFP, and the EGP-2 and cytosine deaminase cDNA sequences were cloned downstream of the 3.4 kb promoter region as depicted schematically in Figure 1 . The obtained plasmids were transfected into the EGP-2-positive and -negative cells and assayed for luciferase, GFP, EGP-2 or CD expression as described. Identical constructs with either the CMV promoter or without any 5 0 regulatory sequences were used as positive and negative control, respectively. Table 2 shows the results of these transfection experiments. EGP-2 promoter-driven expression of luciferase, GFP and CD was observed in the EGP-2-positive carcinoma cell lines SW948 and GLC-45. EGP-2 promoter-driven expression of EGP-2 cDNA could not be determined in these cell lines due to the presence of endogenous EGP-2. No expression of luciferase, GFP, EGP-2, or CD could be observed in the EGP-2-negative GLC-1, FLF, and HUVEC cells upon transfection. In all cell lines expression of the heterologous genes could be detected when driven by the CMV promoter. Furthermore, PCR analysis on genomic DNA of the GLC1 and FLF cells, using exon 9 as well as promoter region spanning primers demonstrated that the lack of EGP-2 expression in these cells was not due to genomic deletion of the EGP-2 gene itself (Fig 3) . Therefore, it is most likely that presence or absence of regulatory proteins in Table 1 Presence and absence of (epithelial-specific) consensus transcription factor recognition sequences in the proximal 5 0 flanking region of the EGP-2 gene GA733-2 Present Absent Name Consensus Sequence Position Name Consensus
Consensus sequences identified using the TRANSFAC v3.2 database. The first two columns contain the names of the transcription factors and the consensus recognition sites present. The next two columns show the sequence of the EGP-2 promoter and the nucleotide position relative to the putative transcription start site. The following two columns, the names of transcription factors and consensus recognition sites absent. S, G or C; W, A or T; Y, C or T; N, A or C or G or T; K, G or T; M, A or C, and R, A or G. HLH, helixloop-helix transcription factor recognition sites.
these cells causes the lack of EGP-2 expression. These results show that the 3.4 kb EGP-2 5 0 regulatory sequences contain a functional promoter and suggest that the activity of this promoter is restricted to cells expressing EGP-2 due to cell type-specific gene transcription.
To identify regions in the EGP-2 promoter responsible for the observed epithelial cell-specific expression, deletion analyses were performed. Deletion constructs of the p39 E GFP reporter plasmid containing À3340 nucleotides upstream of the transcription initiation site, the transcription initiation site, and þ 93 nucleotides of the untranslated region of exon 1 (Fig 1d) were generated and transfected into COS-7, SW948, FLF, and HUVEC cells and analyzed for GFP expression. All constructs generated were sequenced and all of the sequences were identical to the cloned and sequenced 5 0 region of EGP-2 genomic DNA as depicted in Figure 2 . As shown in Figure 4 , minimal promoter activity was confined to -177 bp upstream sequences, since transfection of construct p39
EPstI showed maximal expression of GFP in both the COS-7 and SW948 cell lines. This construct contains the initiation of transcription consensus, two putative Sp-1 and AP-2 binding sites, an AP-1 and NF-kB consensus sequence, and contains half of the first putative E-pal sequence. Deletion of the AP-1 and one of the Sp-1 bindings sites reduced the promoter activity to approximately 60% of the maximum EGP-2 promoter activity (p39 E12-3 ), whereas removal of the Inr further reduced the promoter activity with approximately 25% (p39 E12-2 ). GFP expression directed by À351 (p39 E11-1 ) promoter sequences was not epithelial specific since promoter activity of constructs covering this promoter region was also observed in the FLF and HUVEC. Transfection of an additional -337 bps (p39 E4-1 ) starting at -688, did confine epithelial-specific expression to the GFP reporter construct since only limited GFP expression could be detected in FLF and HUVEC upon transfection, whereas maximal expression of GFP was observed in the COS-7 and SW948 cell lines. Deletion of -2803 to -177 of the EGP-2 promoter region resulted in maximal GFP expression in all cell lines tested implicating that this region harbors epithelial-specific transcriptional elements. Complete silencing of GFP expression in FLF cells was achieved using À2324 bp of upstream sequences (p39 E17-1 ). The construct p39 E17-1 contains additional 246 bp of EGP-2 promoter sequences that covers a consensus-binding site for an epithelial specific ets-1 (ESE-1). Removal of this ESE-1 site and the nearby AP-1 consensus binding site by XcaI and ScaI digestion demonstrated that this part of the 3.4 kb EGP-2 promoter sequences was important for maintenance of the cell type specificity in FLF cells. However, since expression was not completely restored in the FLF and not regained by this construct in HUVEC other specific regulation factors, as yet unknown, must be of importance as well.
To evaluate the EGP-2 promoter for its capacity to induce tumor cell-specific death, we cloned the 3.4 kb EGP-2 promoter sequences upstream of the HSV-TK gene. As a positive control the CMV-promoter-driven HSV-TK construct was used whereas the CMV promoterdriven GFP construct functioned as negative control and as indicator of the number of cells transfected. Cells were transiently transfected as this mimics best actual EGP-2 promoter-driven gene therapy of EGP-2 expressing carcinomas in humans. GCV sensitivity induced by expression of the CMV-TK construct and determined by MTT could not be measured in cell lines with a transfection efficiency beneath approximately 30%. Maximal CMV-TK induced GCV sensitivity was observed in SKOV-3, U373 MG and B16-F10 cell lines at a concentration of 0.1 mM or higher and appeared to correlate with the transfection efficiency (Fig 5) . Expression of TK in these cell lines was immunohistochemically confirmed (data not shown). Barely any sensitivity to GCV was observed in these cell lines upon transfection with the CMV-GFP construct. Upon transfection with the EGP-2-TK construct sensitivity to GCV could only be observed in the EGP-2 expressing ovarian carcinoma cell line SKOV-3. This demonstrates that the 3.4 kb EGP-2 promoter is sufficient enough to drive EGP-2 expressing carcinoma-cell-specific killing via the HSV-TK suicide gene/GCV prodrug system.
Discussion
Here, we report the isolation and characterization of 3. 4 kb of cis-acting DNA sequences that control the expression of the gene encoding the pancarcinoma 
n.a. + + + + EGP-2, GFP, luciferase, and CD expression directed by the EGP-2 5 0 proximal promoter region in the EGP-2 expressing carcinoma cell lines, SW948 and GLC-45, and in the EGP-2 negative cell lines GLC-1, fetal lung fibroblast (FLF), and human umbilical cord-derived endothelial cells (HUVEC). COS-7 cells were used to establish the functionality of the generated constructs. n.a. not applicable. Table  represents the results of three independent transfection experiments with freshly isolated DNA. 0 -untranslated region 14 is underlined. The ATG start codon and protein-encoding region is depicted bold, underlined in italic. Gray shadowed sequences were defined as repeat sequences using the mask repeat sequence program. The brackets depict the start of the deletion construct named at the side. Nucleotide positions are numbered to the right with respect to the transcription initiation site at þ 1.
associated-antigen EGP-2, also known as GA733-2, Ep-CAM or 17-1A, and the successful use of this promoter region to direct epithelial-specific expression of a number of heterologous genes.
Analysis of the EGP-2 5 0 regulatory sequences, revealed several homologies to known transcriptional regulatory sequences. Although no TATA or CAAT box could be distinguished, other typical eukaryotic promoter elements like an initiator (Inr) consensus and GC boxes are present. 17 Previous studies showed that EGP-2 is downregulated upon treatment with TNFa, TPA and IFNa, via NF-kB. 18, 19 However, we screened the proximal 5 0 flanking region especially for consensus recognition sequences of transcription factors known to be involved in epithelial-specific gene expression. The GC boxes upstream of the Inr confirm to a consensus-binding site for the transcription factor Sp1. Sp1 can initiate transcription by recruiting the RNA polymerase holoenzyme to the promoter and has been described to be involved in epithelial-specific expression upon interaction with an Ets consensus-binding element. 20, 21 Although numerous Ets consensus-binding sites are present throughout the EGP-2-promoter sequences no Ets consensus-binding site is present near the two Sp1 sites closest to the Inr. Sp1 and Ets consensus-binding sites located in proximity can be found more upstream. Examination of the EGP-2 promoter for the presence of other known epithelial specificity-conveying consensus sequences yielded two imperfect E-pal-like sequences and an ESE-1 consensus-binding site. The E-pal sequence contributes to the epithelial-specific expression of the E-cadherin gene and E-pal-like sequences are involved in the epithelialspecific expression of MUC1 and Integrin a6.
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However, these sequences all harbor two CANNTG consensus-binding sites for helix-loop-helix transcription factors and not one, like the two putative E-pal-like sequences found in the EGP-2 promoter. However, only one-half of the E-pal sequence is necessary for its function. 25 The EGP-2 regulatory sequences analyzed here are capable of directing heterologous gene expression in epithelial cells normally expressing EGP-2 but not in non-EGP-2-expressing cells. By deletion analysis it was established that 177 bp of the 5 0 flanking sequence are sufficient to give maximal promoter activity, whereas 687 bp of the 5 0 flanking region are sufficient to confer epithelial specificity. In the FLF cells, expression directed by the EGP-2 promoter seems to depend on a combination of yet undefined cell type-specific elements and the ESE-1 element present. The ESE-1 binding site, situated 26 This distribution pattern strongly resembles the EGP-2 distribution pattern found in the EGP-2 expressing transgenic mouse model, we generated using the total of 55 kb EGP-2 encoding and regulatory genomic sequences from the isolated BAC clone. 27 The TK gene is capable of converting the nontoxic prodrug GCV into the toxic monophosphate form leading to the death of TK expressing cells. We show that the EGP-2 promoter sequences are capable of directing the TK gene expression in an EGP-2 expressing-carcinomaspecific manner. However, no bystander effect, which is often reported as an important aspect of the HSV-TK/ GCV antitumor therapy, could be observed in the cell lines used. 28 In applying enzyme/prodrug therapy it is crucial to specifically damage tumor cells without affecting normal cells. The EGP-2 regulatory sequences described here are sufficient to enhance the specificity in carcinoma-directed suicide gene therapy. Use of these sequences should enhance the safety and efficacy of vector-based carcinoma-specific gene therapy approaches. 
